The DOI matches its Crossref record.
Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation.
Open accessAbstract
Although very similar in sequence, the four subclasses of human immunoglobulin G (IgG) differ markedly in their ability to activate complement. Glu318-Lys320-Lys322 has been identified as a key binding motif for the first component of complement, C1q, and is present in all isotypes of Ig capable of activating complement. This motif, however, is present in all subclasses of human IgG, including those that show little (IgG2) or even no (IgG4) complement activity. Using point mutants of chimeric antibodies, we have identified specific residues responsible for the differing ability of the IgG subclasses to fix complement. In particular, we show that Ser at position 331 in gamma 4 is critical for determining the inability of that isotype to bind C1q and activate complement. Additionally, we provide further evidence that levels of C1q binding do not necessarily correlate with levels of complement activity, and that C1q binding alone is not sufficient for complement activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
IgG Subclasses and Allotypes: From Structure to Effector Functions
Vidarsson, G., Dekkers, G., & Rispens, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00520 · Cited by 2,667
Stone, J. H., Zen, Y., & Deshpande, V. (2012) · New England Journal of Medicine · doi:10.1056/nejmra1104650 · Cited by 2,616
Kamisawa, T., Zen, Y., Pillai, S., & Stone, J. H. (2015) · The Lancet · doi:10.1016/s0140-6736(14)60720-0 · Cited by 1,212
Properties of mouse and human IgG receptors and their contribution to disease models
Bruhns, P. (2012) · Blood · doi:10.1182/blood-2012-01-380121 · Cited by 847
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778
TACI-Ig Neutralizes Molecules Critical for B Cell Development and Autoimmune Disease
Gross, J. A., Dillon, S. R., Mudri, S., Johnston, J., Littau, A., Roque, R., Rixon, M., Schou, O., Foley, K. P., Haugen, H., et al. (2001) · Immunity · doi:10.1016/s1074-7613(01)00183-2 · Cited by 626
Follicular B helper T cells in antibody responses and autoimmunity
Vinuesa, C. G., Tangye, S. G., Moser, B., & Mackay, C. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1714 · Cited by 624
Mouse and human FcR effector functions
Bruhns, P., & Jönsson, F. (2015) · Immunological Reviews · doi:10.1111/imr.12350 · Cited by 579
Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc
Idusogie, E. E., Presta, L. G., Gazzano-Santoro, H., Totpal, K., Wong, P. Y., Ultsch, M., Meng, Y. G., & Mulkerrin, M. G. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.8.4178 · Cited by 424
The carbohydrate-recognition domain of Dectin-2 is a C-type lectin with specificity for high mannose
McGreal, E. P., Rosas, M., Brown, G. D., Zamze, S., Wong, S. Y. C., Gordon, S., Martinez-Pomares, L., & Taylor, P. R. (2006) · Glycobiology · doi:10.1093/glycob/cwj077 · Cited by 379
Kanda, Y., Yamada, T., Mori, K., Okazaki, A., Inoue, M., Kitajima-Miyama, K., Kuni-Kamochi, R., Nakano, R., Yano, K., Kakita, S., et al. (2007) · Glycobiology · doi:10.1093/glycob/cwl057 · Cited by 372
Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv
Thomas, T. C., Rollins, S. A., Rother, R. P., Giannoni, M. A., Hartman, S. L., Elliott, E. A., Nye, S. H., Matis, L. A., Squinto, S. P., & Evans, M. J. (1996) · Molecular Immunology · doi:10.1016/s0161-5890(96)00078-8 · Cited by 363
IgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
What is IgG4? A review of the biology of a unique immunoglobulin subtype
Nirula, A., Glaser, S. M., Kalled, S. L., & Taylora, F. R. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e3283412fd4 · Cited by 309
Fiebiger, E., Maurer, D., Holub, H., Reininger, B., Hartmann, G., Woisetschläger, M., Kinet, J. P., & Stingl, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118325 · Cited by 294
Hezareh, M., Hessell, A. J., Jensen, R. C., van de Winkel, J. G. J., & Parren, P. W. H. I. (2001) · Journal of Virology · doi:10.1128/jvi.75.24.12161-12168.2001 · Cited by 294
IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury
Lefaucheur, C., Viglietti, D., Bentlejewski, C., Duong van Huyen, J.-P., Vernerey, D., Aubert, O., Verine, J., Jouven, X., Legendre, C., Glotz, D., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014111120 · Cited by 292
An Engineered Human IgG1 Antibody with Longer Serum Half-Life
Hinton, P. R., Xiong, J. M., Johlfs, M. G., Tang, M. T., Keller, S., & Tsurushita, N. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.1.346 · Cited by 282
The Unique Properties of IgG4 and Its Roles in Health and Disease
Rispens, T., & Huijbers, M. G. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00871-z · Cited by 282
Structure of full-length human anti-PD1 therapeutic IgG4 antibody pembrolizumab
Scapin, G., Yang, X., Prosise, W. W., McCoy, M., Reichert, P., Johnston, J. M., Kashi, R. S., & Strickland, C. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3129 · Cited by 259
The clinical significance of allergen-specific IgG4 in allergic diseases
Qin, L., Tang, L.-F., Cheng, L., & Wang, H.-Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032909 · Cited by 71
Lightle, S., Aykent, S., Lacher, N., Mitaksov, V., Wells, K., Zobel, J., & Oliphant, T. (2010) · Protein Science · doi:10.1002/pro.352 · Cited by 31
Metadata
- Authors
- Tao, M. H., Smith, R. I., & Morrison, S. L.
- Venue
- The Journal of experimental medicine
- Publisher
- Rockefeller University Press
- Published
- 1993-08-01
- Volume
- 178
- Issue
- 2
- Pages
- 661-667
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2160956924
- Cited by
- 251
- References
- 0
- FWCI
- 2.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.